Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloidosis

Larysa Sanchez, MD, Heather J Landau, MD, Cara A. Rosenbaum, MD, Alex Abrahams, Cindy Chin, Brielle Liotta, BS, Natalie Agudo, RN, Sheetal Ramnath, Elizabeth Hoover, BS, Hafsa Rahman, Umut Ozbek, PhD, Oscar B Lahoud, MD, Hani Hassoun, MD, Keren Osman, MD

Blood (2019) 134 (Supplement_1): 3128.

https://doi.org/10.1182/blood-2019-126023

Published: 2019

Journal Articles

Feasibility, Tolerability, and Patient-Reported Outcomes with Pharmacokinetic (PK)-Directed Dosing of Evomela® (propylene glycol free melphalan) for Multiple Myeloma and AL Amyloidosis Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT)

Gunjan L. Shah, MD, Andrew Lin, PharmD, Ryan Schofield, MS, Caitlin Sarubbi, AB, Elaina V. Preston, PA-C,MPH, Sean M. Devlin, PhD, Valkal Bhatt, PharmD, Stephen J. Harnicar, PharmD, Elizabeth Hoover, BS, David J. Chung, MDPhD, Parastoo B. Dahi, MD, Guenther Koehne, MDPhD, Roni Tamari, MD, Dean Carlow, MDPhD, Sergio A. Giralt, MD, Heather Landau, MD

Blood (2017) 130 (Supplement 1): 2023.

https://doi.org/10.1182/blood.V130.Suppl_1.2023.2023

Published: 2017

Journal Articles

Fractionated Stem Cell Infusions for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Kevin Wood, MD, Sergio A Giralt, MD, Guenther Koehne, MD, PhD, David Chung, MD PhD, Nikoletta Lendvai, MD PhD, Hani Hassoun, MD, Alex Lesokhin, MD, Elizabeth Hoover, Sean Devlin, PhD, Heather Landau, MD

Blood (2012) 120 (21): 4550.

https://doi.org/10.1182/blood.V120.21.4550.4550

Published: 2012

Journal Articles

Urinary Excretion of Epinephrine and Dopamine Correlates with Efficiency of G-CSF Mobilized Stem Cells in Patients with AL Amyloidosis

Heather Landau, MD, Hani Hassoun, MD, James E. Hoffman, MD, Christina Bello, Elizabeth Hoover, Elyn Riedel, Paul S. Frenette, MD, FRCPC, Raymond L. Comenzo, MD

Blood (2011) 118 (21): 316.

https://doi.org/10.1182/blood.V118.21.316.316

Published: 2011

Journal Articles

Maintained Hematologic and Organ Responses at Two Years Following Stem Cell Transplant In Systemic Light-Chain Amyloidosis (AL) Using Short-Course Bortezomib and Dexamethasone Consolidation Therapy

Heather Landau, MD, Hani Hassoun, MD, Michael A. Rosenzweig, MD, Christina Bello, Elizabeth Hoover, Elyn Riedel, Alex Lesokhin, MD, Nikoletta Lendvai, MD, PhD, Adam Cohen, MD, Stephen Nimer, Raymond L. Comenzo, MD

Blood (2010) 116 (21): 2391.

https://doi.org/10.1182/blood.V116.21.2391.2391

Published: 2010

Journal Articles

Adjuvant Bortezomib and Dexamethasone Following Risk-Adapted Melphalan and Stem Cell Transplant in Systemic Light-Chain Amyloidosis (AL): A Phase II Study.

Heather Landau, MD, Hani Hassoun, MD, Adam D Cohen, MD, Alexander Lesokhin, MD, Christina Bello, Elizabeth Hoover, Elyn R Riedel, MD, Jennifer Ciminiello, RN, NP, Emily McCullagh, RN, NP-C, OCN, Stephen D Nimer, MD, Raymond Comenzo, MD

Blood (2009) 114 (22): 533.

https://doi.org/10.1182/blood.V114.22.533.533

Published: 2009

Journal Articles

Early Adjuvant Treatment after Risk-Adapted Autologous Stem Cell Transplant for Systemic Light-Chain Amyloidosis: Increased Hospitalizations and Impaired Immune Recovery but Improved Responses and Overall Survival.

James E. Hoffman, MD, Hani Hassoun, MD, Heather Landau, MD, Elizabeth Hoover, Adam Cohen, MD, Stephen Nimer, MD, Raymond Comenzo, MD

Blood (2008) 112 (11): 3329.

https://doi.org/10.1182/blood.V112.11.3329.3329

Published: 2008

Journal Articles

Sequential Administration of Bortezomib, Liposomal Doxorubicin and Dexamethasone (BDD) Followed by Thalidomide and Dexamethasone (TD) Results in Rapid Control of Untreated High-Risk Multiple Myeloma (MM) and Improves Depth of Response

Heather Landau, MD, Hani Hassoun, MD, Adam Cohen, MD, Elizabeth Hoover, Tarun Kewalramani, MD, Adam Boruchov, MD, Virginia Klimek, MD, Lillian Reich, MD, Elyn Riedel, Neeta Pandit-Taskar, MD, Stephen D. Nimer, MD, Raymond L. Comenzo, MD

Blood (2008) 112 (11): 3712.

https://doi.org/10.1182/blood.V112.11.3712.3712

Published: 2008

NARROW

A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloidosis

Feasibility, Tolerability, and Patient-Reported Outcomes with Pharmacokinetic (PK)-Directed Dosing of Evomela® (propylene glycol free melphalan) for Multiple Myeloma and AL Amyloidosis Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT)

Fractionated Stem Cell Infusions for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Urinary Excretion of Epinephrine and Dopamine Correlates with Efficiency of G-CSF Mobilized Stem Cells in Patients with AL Amyloidosis

Maintained Hematologic and Organ Responses at Two Years Following Stem Cell Transplant In Systemic Light-Chain Amyloidosis (AL) Using Short-Course Bortezomib and Dexamethasone Consolidation Therapy

Adjuvant Bortezomib and Dexamethasone Following Risk-Adapted Melphalan and Stem Cell Transplant in Systemic Light-Chain Amyloidosis (AL): A Phase II Study.

Early Adjuvant Treatment after Risk-Adapted Autologous Stem Cell Transplant for Systemic Light-Chain Amyloidosis: Increased Hospitalizations and Impaired Immune Recovery but Improved Responses and Overall Survival.

Sequential Administration of Bortezomib, Liposomal Doxorubicin and Dexamethasone (BDD) Followed by Thalidomide and Dexamethasone (TD) Results in Rapid Control of Untreated High-Risk Multiple Myeloma (MM) and Improves Depth of Response

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only